NCT01195298Unknown2 期
Phase II Clinical Study of Bevacizumab in Combination With Capecitabine as First-line Treatment in Elderly Patients With Metastatic Breast Cancer
South Eastern European Research Oncology Group2 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2010年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 88
- 试验地点
- 2
- 主要终点
- Time to treatment progression
研究概览
简要总结
This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab administered as first-line treatment of previously untreated elderly patients, older than 70 years, with metastatic or locally recurrent breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent obtained prior to initiation of any study specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the Protocol code: ML22373 Protocol SEEROG: version 1.
- •Date: October 15, 2009 3 study requirements;
- •Age ≥70 years;
- •Pathologically confirmed and documented metastatic breast cancer or locally recurrent breast cancer not amenable to curative treatment. Complete radiology and tumor measurement workup must be completed within 4 weeks prior to first study treatment;
- •Measurable disease according to RECIST criteria;
- •HER2 negative disease;
- •No prior treatment for metastatic or locally recurrent disease;
- •Prior radiotherapy is allowed if delivered at least 2 weeks before enrolment in the study and for the relief of metastatic bone pain, and provided that no more than 30% of marrow bearing bone was irradiated and that target lesions were not included in the radiotherapy field;
- •Not suitable for aggressive chemotherapy regimen in the opinion of the investigator;
- •Performance status ECOG 0 - 2.
排除标准
- •Any prior neoadjuvant or adjuvant treatment with anthracyclines completed less than 6 months prior to enrolment. The maximum cumulative dose received must not have exceeded 360 mg/m2 for doxorubicin or 720 mg/m2 for epirubicin. Prior anti-epidermal growth factor therapy is allowed;
- •Concurrent hormonal therapy; however previous hormonal therapy is allowed for adjuvant, locally recurrent, or metastatic breast cancer if completed within ≥1 months prior to enrolment;
- •History or clinical evidence of brain metastases. If there is any clinical suspicion of brain metastasis, a computerized tomography (CT) scan or magnetic resonance imaging (MRI) of the brain must be conducted within 4 weeks prior to enrolment;
- •Other malignancy (including primary brain tumors) within the Protocol code: ML22373 Protocol SEEROG: version 1.
- •Date: October 15, 2009 4 last 5 years, which could affect the diagnosis or assessment of breast cancer, except for adequately treated carcinoma in situ of the cervix, squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer;
- •Life expectancy < 12 weeks;
- •Any of the following abnormal values:
- •Inadequate bone marrow function: hemoglobin (Hb) < 8.0 g/dL, absolute neutrophil count (ANC) < 1.5 x 109/L, or platelet count < 100 x 109/L;
- •Inadequate liver function: AST/SGOT or ALT/SGPT > 2.5 x upper limit of normal (ULN) or > 5 x ULN in patients with liver metastases), serum alkaline phosphatase > 2.5 ULN or > 5 x ULN in patients with liver metastases, or > 10 x ULN in patients with bone metastases or total bilirubin > 2 x ULN;
- •Moderate or severe renal impairment: creatinine clearance ≤50 mL/min (calculated according to the cockcroft and Gault formula; see Appendix 1), or serum creatinine > 1.5 x ULN;
- •Chronic daily treatment with aspirin (> 325 mg/day) or clopidogrel (> 75 mg / day);
- •Chronic daily treatment with corticosteroids (dose of > 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids);
- •Requirement for concurrent use of the antiviral agents sorivudine or brivudine;
- •Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to enrolment, or anticipation of the need for major surgery during the course of the study treatment;
- •Minor surgical procedures, within 24 hours prior to enrolment;
- •Current or recent (within the 30 days prior to starting study treatment) treatment with another investigational drug or participation in another investigational study.
- •Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (i.e. active) cardiovascular disease, including:
- •Cerebrovascular accident/stroke (≤ 6 months prior to enrolment)
结局指标
主要结局
Time to treatment progression
时间窗: average 5 years
followed until death
次要结局
- overall response rate in patients with measurable disease at baseline(average 5 years)
- safety and tolerability(average 5 years)
- Clinical benefit (complete response, partial response and stable disease) in patients with measurable disease at baseline(average 5 years)
- progression-free survival(average 5 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)Brain NeoplasmsNon-Small Cell Lung CancerNCT00312728Genentech, Inc.115
招募中
2 期
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabOvarian, Fallopian Tube and Primary Peritoneal CarcinomaNCT06141265Peking University Cancer Hospital & Institute116
进行中（未招募）
1 期
Estudio abierto fase II de bevacizumab en combinación con paclitaxel y gemcitabina como tratamiento de primera línea en pacientes diagnosticados de carcinoma de mama metastasico o localmente avanzado HER-2 negativo - AvaluzEUCTR2008-003657-32-ESRoche Farma S.A.85
已完成
3 期
A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric CancerGastric CancerNCT00887822Hoffmann-La Roche202
已完成
2 期
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal CancerLocally Advanced Rectal CancerNCT00828672Universitaire Ziekenhuizen KU Leuven84